NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based provider of innovative exchange traded funds (ETFs), today announced the launch of the Tema International Durable Quality ETF. ITOL ...
Company leveraging iTOL-100 to advance a pipeline of programs that have the potential to cure diseases, such as Type 1 Diabetes, without the need for life-long immunosuppression MIAMI, FL / ACCESSWIRE ...
Company leveraging iTOL-100 to advance a pipeline of programs that have the potential to cure diseases, such as Type 1 Diabetes, without the need for life-long immunosuppression MIAMI, FL / ACCESSWIRE ...
Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression Kadimastem and iTolerance believe that the ...
Kadimastem Ltd. and Itolerance Inc. have held a type B pre-IND meeting with the FDA regarding the development of ITOL-102, an investigational biologic for the treatment and potential cure of type 1 ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NLS Pharmaceutics ( (NLSP)) has shared an ...
*Today’s High/Low is only updated during regular trading hours; and does not include trades occurring in pre-market or after-hours. Nasdaq Official Closing Price (NOCP)" is a process for identifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results